Bone Biologics Corp. (NASDAQ:BBLG) Sees Significant Decrease in Short Interest

Bone Biologics Corp. (NASDAQ:BBLG) was the recipient of a large drop in short interest in February. As of February 27th, there was short interest totaling 30,363 shares, a drop of 27.3% from the February 12th total of 41,755 shares. Approximately 1.8% of the shares of the stock are short sold. Based on an average daily volume of 16,236 shares, the days-to-cover ratio is currently 1.9 days. Based on an average daily volume of 16,236 shares, the days-to-cover ratio is currently 1.9 days. Approximately 1.8% of the shares of the stock are short sold.

Institutional Investors Weigh In On Bone Biologics

An institutional investor recently raised its position in Bone Biologics stock. DRW Securities LLC lifted its stake in shares of Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,576 shares of the company’s stock after purchasing an additional 12,549 shares during the period. DRW Securities LLC owned approximately 1.31% of Bone Biologics worth $34,000 at the end of the most recent quarter. Institutional investors own 34.30% of the company’s stock.

Bone Biologics Price Performance

NASDAQ BBLG opened at $1.22 on Friday. Bone Biologics has a 12 month low of $1.11 and a 12 month high of $6.75. The company has a market capitalization of $2.19 million, a P/E ratio of -0.32 and a beta of 0.78. The company’s 50 day simple moving average is $1.43 and its 200 day simple moving average is $1.82.

Bone Biologics (NASDAQ:BBLG) last issued its earnings results on Monday, March 2nd. The company reported ($0.34) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.34). On average, analysts anticipate that Bone Biologics will post -5 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e)” rating on shares of Bone Biologics in a research note on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Bone Biologics presently has a consensus rating of “Sell”.

Bone Biologics Company Profile

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.